Literature DB >> 15316646

[Iloprost and selective pulmonary vasodilation. Clinical results of intraoperative and postoperative inhalation of iloprost].

F Langer1, W Wilhelm, H Lausberg, H-J Schäfers.   

Abstract

Pulmonary hypertension is a major risk factor in cardiac surgery and has significant impact on morbidity and mortality in the perioperative period. Nitric oxide (NO) is considered to be the gold standard for treatment of pulmonary hypertension in the perioperative setting. The aerosolized administration of the prostacyclin analogue iloprost is a new alternative with similar pulmonary-selective vasodilation and virtually no systemic side-effects. Relevant complications including increased postoperative bleeding have not been observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316646     DOI: 10.1007/s00101-004-0715-z

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  23 in total

1.  Risk factors for early mortality after valve surgery in Europe in the 1990s: lessons from the EuroSCORE pilot program.

Authors:  F Roques; S A Nashef; P Michel
Journal:  J Heart Valve Dis       Date:  2001-09

2.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

Authors:  R M Tuder; C D Cool; M W Geraci; J Wang; S H Abman; L Wright; D Badesch; N F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

3.  Ten years experience with lung and heart-lung transplantation in primary and secondary pulmonary hypertension.

Authors:  U Franke; K Wiebe; W Harringer; T Franke; T Wittwer; T Wahlers; A Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2000-10       Impact factor: 4.191

4.  Caution with use of inhaled nitric oxide.

Authors:  J B Warren; T Higenbottam
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

5.  Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group.

Authors:  H Olschewski; H A Ghofrani; T Schmehl; J Winkler; H Wilkens; M M Höper; J Behr; F X Kleber; W Seeger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

6.  Predictors of mortality in pulmonary thromboendarterectomy.

Authors:  R S Hartz; J G Byrne; S Levitsky; J Park; S Rich
Journal:  Ann Thorac Surg       Date:  1996-11       Impact factor: 4.330

7.  Bleeding time prolongation and NO inhalation.

Authors:  M Högman; C Frostell; H Arnberg; G Hedenstierna
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

8.  Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass.

Authors:  A Haraldsson; N Kieler-Jensen; H Wadenvik; S E Ricksten
Journal:  Intensive Care Med       Date:  2000-02       Impact factor: 17.440

9.  Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery.

Authors:  D L Reich; C A Bodian; M Krol; M Kuroda; T Osinski; D M Thys
Journal:  Anesth Analg       Date:  1999-10       Impact factor: 5.108

10.  Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost.

Authors:  H Olschewski; H A Ghofrani; D Walmrath; B Temmesfeld-Wollbrück; F Grimminger; W Seeger
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.